Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis

C Van Rechem, JC Black, M Boukhali, MJ Aryee… - Cancer discovery, 2015 - AACR
C Van Rechem, JC Black, M Boukhali, MJ Aryee, S Gräslund, W Haas, CH Benes…
Cancer discovery, 2015AACR
Chromatin-modifying enzymes are predominantly nuclear; however, these factors are also
localized to the cytoplasm, and very little is known about their role in this compartment. In
this report, we reveal a non–chromatin-linked role for the lysine-specific demethylase
KDM4A. We demonstrate that KDM4A interacts with the translation initiation complex and
affects the distribution of translation initiation factors within polysome fractions. Furthermore,
KDM4A depletion reduced protein synthesis and enhanced the protein synthesis …
Abstract
Chromatin-modifying enzymes are predominantly nuclear; however, these factors are also localized to the cytoplasm, and very little is known about their role in this compartment. In this report, we reveal a non–chromatin-linked role for the lysine-specific demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation complex and affects the distribution of translation initiation factors within polysome fractions. Furthermore, KDM4A depletion reduced protein synthesis and enhanced the protein synthesis suppression observed with mTOR inhibitors, which paralleled an increased sensitivity to these drugs. Finally, we demonstrate that JIB-04, a JmjC demethylase inhibitor, suppresses translation initiation and enhances mTOR inhibitor sensitivity. These data highlight an unexpected cytoplasmic role for KDM4A in regulating protein synthesis and suggest novel potential therapeutic applications for this class of enzyme.
Significance: This report documents an unexpected cytoplasmic role for the lysine demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation machinery, regulates protein synthesis and, upon coinhibition with mTOR inhibitors, enhances the translation suppression and cell sensitivity to these therapeutics. Cancer Discov; 5(3); 255–63. ©2015 AACR.
See related commentary by Rothbart et al., p. 228
See related article by Van Rechem et al., p. 245
This article is highlighted in the In This Issue feature, p. 213
AACR